Go Pro
David Lebowitz

David Lebowitz Analyst Performance

Senior Research Analyst at Citigroup

David Lebowitz is a stock analyst at Citigroup in the healthcare sector, covering 19 publicly traded companies. Over the past year, David Lebowitz has issued 21 stock ratings, including strong buy, buy, and hold recommendations. While full access to David Lebowitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Lebowitz's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
43 Last 1 Years
Buy Recommendations
74.42% 32 Buy Ratings
Companies Covered
19 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy9.3%4 ratings
Buy65.1%28 ratings
Hold23.3%10 ratings
Sell2.3%1 ratings

Out of 43 total stock ratings issued by David Lebowitz at Citigroup, the majority (65.1%) have been Buy recommendations, followed by 23.3% Hold, 9.3% Strong Buy, and 2.3% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
94.7% of companies on NASDAQ
18 companies
NYSEAMERICAN
5.3% of companies on NYSEAMERICAN
1 company

David Lebowitz, an analyst at Citigroup, currently covers 19 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
19 companies
100.0%

David Lebowitz of Citigroup specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
18 companies
94.7%
HEALTHCARE TECHNOLOGY
1 company
5.3%

About David Lebowitz

David Lebowitz currently works at Citigroup Global Markets, Inc. (Broker), as Senior Research Analyst from 2021. Mr. Lebowitz also formerly worked at Piper Sandler & Co. (Broker), as Research Analyst from 2013 to 2014, Morgan Stanley & Co. LLC, as Equity Analyst from 2015 to 2021, Summit Technology, Inc., as Regulatory Specialist in 1999, SMH Capital, Inc. (Capital Markets), as Vice President & Senior Research Analyst from 2007 to 2008, Thomas Weisel Partners LLC, as Vice President & Senior Research Analyst from 2003 to 2006, Janney Montgomery Scott LLC, as Research Analyst from 2014 to 2015, and SG Cowen Securities Corp., as Equity Research Associate in 2002. Mr. Lebowitz received his graduate degree from The Trustees of Columbia University in The City of New York, undergraduate degree from Brandeis University, and Masters Business Admin degree from The Leonard N Stern School of Business.
Follow on LinkedIn

David Lebowitz's Ratings History at Citigroup

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8/31/2026Reiterated Rating$241.04Outperform
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
8/19/2026Initiated Coverage$59.62$60.00Market Perform
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
8/19/2026Initiated Coverage$66.99$98.00Outperform
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8/19/2026Initiated Coverage$228.61$318.00Outperform
Exelixis, Inc. stock logo
EXEL
Exelixis
8/18/2026Initiated Coverage$53.12$54.00Market Perform
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
8/18/2026Initiated Coverage$3.05$9.00Outperform
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
8/18/2026Set Price Target$3.21$11.00Outperform
Aktis Oncology stock logo
AKTS
Aktis Oncology
8/18/2026Initiated Coverage$25.00$37.00Outperform
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/18/2026Initiated Coverage$248.85$319.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
8/18/2026Initiated Coverage$24.92$35.00Outperform
Aktis Oncology stock logo
AKTS
Aktis Oncology
8/18/2026Initiated Coverage$25.02$37.00Outperform
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8/18/2026Upgrade$242.61Strong-Buy
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/18/2026Initiated Coverage$259.62$319.00Outperform
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
8/18/2026Upgrade$25.86Strong-Buy
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
8/18/2026Upgrade$69.33Strong-Buy
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
8/18/2026Upgrade$3.48Strong-Buy
Exelixis, Inc. stock logo
EXEL
Exelixis
8/18/2026Initiated Coverage$54.39$54.00Market Perform
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
8/18/2026Upgrade$60.80Hold
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
8/18/2026Initiated Coverage$3.54$9.00Outperform
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
12/22/2025Reiterated Rating$62.72Market Outperform
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
9/3/2025Boost Price Target$60.15$84.00Buy
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
9/2/2025Boost Price Target$48.12$84.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
8/22/2025Boost Price Target$42.29$69.00Buy
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
8/20/2025Lower Price Target$21.36$48.00Buy
Schrodinger, Inc. stock logo
SDGR
Schrodinger
8/15/2025Downgrade$19.45$20.00Neutral
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/8/2025Reiterated Rating$191.49$290.00Buy
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
8/8/2025Lower Price Target$34.11$77.00Buy
Incyte Corporation stock logo
INCY
Incyte
7/30/2025Boost Price Target$78.05$103.00Buy
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
7/24/2025Boost Price Target$33.29$38.00Neutral
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
7/18/2025Boost Price Target$12.46$22.00Buy
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/11/2025Boost Price Target$46.34$67.00Buy
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
7/11/2025Boost Price Target$175.67$243.00Buy
Exelixis, Inc. stock logo
EXEL
Exelixis
5/15/2025Boost Price Target$47.21$56.00Buy
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/9/2025Lower Price Target$8.38$10.00Neutral
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2/28/2025Boost Price Target$9.88$14.00Neutral
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2/21/2025Boost Price Target$36.88$49.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2/20/2025Lower Price Target$32.57$64.00Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2/12/2025Boost Price Target$48.63$45.00Sell
Exelixis, Inc. stock logo
EXEL
Exelixis
2/12/2025Boost Price Target$33.18$45.00Buy
Incyte Corporation stock logo
INCY
Incyte
2/11/2025Lower Price Target$68.30$88.00Buy
Your book attached (Ad)

Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel

Download the Safe Trade Options Formula book for free before access closes
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2/10/2025Downgrade$7.79$4.00Neutral
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2/7/2025Initiated Coverage$46.17$86.00Buy
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2/7/2025Initiated Coverage$31.46$38.00Neutral